Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2013-10-24 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2013年第三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2013 Third Quarter Report" of Kunming Pharmaceutical Group Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2013. The report explicitly states it is a quarterly report and includes unaudited financial statements for the period ending September 30, 2013. The content is comprehensive and includes substantive financial data and analysis for a period shorter than a full fiscal year, which matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and the length and detail confirm it is the report itself, not just a publication announcement. Therefore, the correct classification is IR with high confidence. Q3 2013
2013-10-24 Chinese
关于环保核查事项的说明公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding an environmental protection inspection and the company's response to issues found during the inspection. It details the environmental violations reported by the Ministry of Environmental Protection, the company's corrective actions, and assurances that the issues have been resolved and will not affect ongoing operations. The document is an announcement about environmental and regulatory matters, not a full environmental report or annual report. It does not contain financial data or detailed ESG performance metrics, so it is not an Environmental & Social Information report (SR). It is also not a regulatory filing about financial or governance matters, but rather a specific environmental compliance announcement. Given the content and nature, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2013-10-15 Chinese
关于环保核查事项的公告
Environmental & Social Information Classification · 95% confidence The document is a short announcement from Kunming Pharmaceutical Group regarding an environmental inspection matter. It mentions the company being named by the national environmental protection department as one of 72 companies with environmental violations, but clarifies that the company has not received any official notice and is following up with relevant authorities. The document is brief (396 characters) and serves as a public announcement about an environmental regulatory issue rather than a detailed report or financial filing. It does not contain financial data, audit information, or management changes. It fits best under Environmental & Social Information (SR) as it relates to environmental compliance and disclosures.
2013-10-14 Chinese
2013年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2013 fourth extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results, and legal witness statements confirming the validity of the meeting and resolutions. There is no detailed financial data or comprehensive report content, only the voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2013-09-13 Chinese
2013年第四次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the procedures and legality of a specific shareholders' meeting (the 2013 fourth extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the convening, attendance, and voting procedures of the meeting and concludes that the meeting and resolutions were lawful and valid. It is not a report of financial results, audit, or management discussion, nor is it a voting result announcement or proxy solicitation. It is a legal opinion related to a shareholders' meeting, which does not fit into categories like AGM Information or Declaration of Voting Results. Given the nature and content, this document best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or compliance documents that do not fit other categories.
2013-09-13 Chinese
关于闲置募集资金现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of cash management of idle raised funds. It details agreements with banks for structured deposits and wealth management products using temporarily idle raised funds. The document is relatively short (1731 characters) and focuses on the use of idle raised funds for cash management, including product details, risk ratings, and expected returns. It does not contain financial statements, comprehensive financial data, or detailed financial performance analysis. It is not an annual or interim report, earnings release, or audit report. It is an update on financing-related activities specifically about the management of idle raised funds, which fits the category of Capital/Financing Update (CAP).
2013-08-30 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.